Abstract #2937
Cerebral metabolite biomarkers of Type 2 Diabetes Mellitus, blood glucose measures, and cognitive decline
Frank C.G. van Bussel 1 , Walter H. Backes 1 , Paul A.M. Hofman 1 , Alfons G.H. Kessels 2 , Nicolaas A.J. Puts 3 , Richard A.E. Edden 3 , Tamar M. van Veenendaal 1 , Harm J. van de Haar 1 , Martin P.J. van Boxtel 4 , Miranda T. Schram 5 , Coen D.A. Stehouwer 5 , Joachim E. Wildberger 1 , and Jacobus F.A. Jansen 1
1
Radiology, Maastricht University Medical
Center, Maastricht, Netherlands,
2
Clinical
Epidemiology and Medical Technology Assessment,
Maastricht University Medical Center, Maastricht,
Netherlands,
3
Radiology
and Radiological Science, The Johns Hopkins University
School of Medicine, Baltimore, MD, United States,
4
Psychiatry
and Neuropsychology, Maastricht University Medical
Center, Maastricht, Netherlands,
5
Internal
Medicine, Maastricht University Medical Center,
Maastricht, Netherlands
Type 2 Diabetes Mellitus (T2DM) is associated with
cerebral abnormalities, accelerated cognitive decline,
and dementia. T2DM risk factors such as blood glucose
levels are associated with developing of dementia.
Magnetic resonance spectroscopy provides the opportunity
to study cerebral metabolites. Altered cerebral
metabolic concentrations may be associated with
neurodegeneration. The aim of this study is to examine
if cerebral metabolites constitute a MRI biomarker for
i) T2DM, ii) blood glucose measures, and/or iii)
cognitive status. This study is the first study to
report higher GABA+ levels in subjects with poor blood
glucose control. Unfortunately, no relationship with
cognitive status was observed.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
